Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents
- PMID: 21530092
- PMCID: PMC3094504
- DOI: 10.1016/j.addbeh.2011.03.016
Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents
Abstract
Objective: Behavioral therapies developed specifically for co-occurring disorders remain sparse, and such therapies for comorbid adolescents are particularly rare. This was an evaluation of the long-term (2-year) efficacy of an acute phase trial of manualized cognitive behavioral therapy/motivation enhancement therapy (CBT/MET) vs. naturalistic treatment among adolescents who had signed consent for a treatment study involving the SSRI antidepressant medication fluoxetine and CBT/MET therapy for comorbid major depressive disorder (MDD) and an alcohol use disorder (AUD). We hypothesized that improvements in depressive symptoms and alcohol-related symptoms noted among the subjects who had received CBT/MET would exceed that of those in the naturalistic comparison group that had not received CBT/MET therapy.
Methods: We evaluated levels of depressive symptoms and alcohol-related symptoms at a two-year follow-up evaluation among comorbid MDD/AUD adolescents who had received an acute phase trial of manual-based CBT/MET (in addition to the SSRI medication fluoxetine or placebo) compared to those who had received naturalistic care.
Results: In repeated measures ANOVA, a significant time by enrollment status difference was noted for both depressive symptoms and alcohol-related symptoms across the two-year time period of this study, with those receiving CBT/MET demonstrating superior outcomes compared to those who had not received protocol CBT/MET therapy. No significant difference was noted between those receiving fluoxetine vs. those receiving placebo on any outcome at any time point.
Conclusions: These findings suggest long-term efficacy for an acute phase trial of manualized CBT/MET for treating comorbid MDD/AUD adolescents. Large multi-site studies are warranted to further clarify the efficacy of CBT/MET therapy among various adolescent and young adult comorbid populations.
Copyright © 2011 Elsevier Ltd. All rights reserved.
References
-
- Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, Sly K, Devir H, Terry M. Motivational interviewing among psychiatric inpatients with substance use disorders. Acta Psychiatrica Scandanivica. 2002;106:233–240. - PubMed
-
- Beck AT, Ward CH, Mendelson M, Erbaugh J. Beck Depression Inventory (BDI). In Chapter 22, Mood Disorder Measures. In: John Rush A Jr, MD, First Michael B MD, Blacker Deborah MD, ScD, editors. Handbook of Psychiatric Measures. Second Edition. Washington, D.C: American Psychiatric Publishing, Inc.; 2008. pp. 504–506.
-
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571. - PubMed
-
- Birmaher B, Brent DA, Kolko D, Baugher M, Bridge J, Holder D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Archives of General Psychiatry. 2000;57:29–36. - PubMed
-
- Brent DA, Holder D, Kolko D, Birmaher B, Baugher M, Roth C, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Archives of General Psychiatry. 1997;54:877–885. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AA013370/AA/NIAAA NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- R01 DA019142/DA/NIDA NIH HHS/United States
- R01-DA019142/DA/NIDA NIH HHS/United States
- R01-AA015173/AA/NIAAA NIH HHS/United States
- R01 AA014357/AA/NIAAA NIH HHS/United States
- K24-AA015320/AA/NIAAA NIH HHS/United States
- R01-AA013370/AA/NIAAA NIH HHS/United States
- R01 AA009127/AA/NIAAA NIH HHS/United States
- R01 AA015173/AA/NIAAA NIH HHS/United States
- R01-DA019142-04S1/DA/NIDA NIH HHS/United States
- K24 AA015320/AA/NIAAA NIH HHS/United States
- K02-AA018195/AA/NIAAA NIH HHS/United States
- K02 AA018195/AA/NIAAA NIH HHS/United States
- R01-AA014357/AA/NIAAA NIH HHS/United States
- R01 AG009127/AG/NIA NIH HHS/United States
- P50 DA005605/DA/NIDA NIH HHS/United States
- P50-DA05605/DA/NIDA NIH HHS/United States
- R01-AA019127/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous
